18 results on '"Murthy, Neil"'
Search Results
2. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger -- United States, 2024.
- Author
-
Wodi, A. Patricia, Murthy, Neil, McNally, Veronica V., Daley, Matthew F., and Cineas, Sybil
- Subjects
- *
IMMUNIZATION , *PNEUMOCOCCAL vaccines , *MONOCLONAL antibodies , *POLIOMYELITIS vaccines , *COVID-19 vaccines - Abstract
The article discusses the Advisory Committee on Immunization Practices' approval of the Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger in October 2023. Topics include changes to the 2024 immunization schedule, such as new or updated recommendations for influenza, pneumococcal vaccines, respiratory syncytial virus monoclonal antibody, COVID-19 vaccines, inactivated poliovirus vaccine.
- Published
- 2024
- Full Text
- View/download PDF
3. COVID-19 Vaccination Coverage and Demographic Characteristics of Infants and Children Aged 6 Months--4 Years -- United States, June 20--December 31, 2022.
- Author
-
Patel Murthy, Bhavini, Fast, Hannah E., Zell, Elizabeth, Murthy, Neil, Lu Meng, Shaw, Lauren, Vogt, Tara, Chatham-Stephens, Kevin, Santibanez, Tammy A., Gibbs-Scharf, Lynn, and Harris, LaTreace Q.
- Subjects
COVID-19 vaccines ,DISEASES ,IMMUNIZATION ,HOSPITAL care ,POPULATION - Abstract
The article presents the discussion on COVID-19 illness and hospitalization being more common among older adults. Topics include CDC by jurisdictions, pharmacies, and federal entities through immunization information systems (IISs); and tests for statistical significance being notconducted due to the data reflecting the U.S. population not based on population samples.
- Published
- 2023
- Full Text
- View/download PDF
4. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older -- United States, 2023.
- Author
-
Murthy, Neil, Wodi, A. Patricia, McNally, Veronica, Cineas, Sybil, and Ault, Kevin
- Subjects
- *
IMMUNIZATION , *ADULTS , *INFLUENZA vaccines , *PNEUMOCOCCAL vaccines - Abstract
The article focuses on the recommendation of Immunization Schedule for adults aged nineteen years or older by Advisory Committee on Immunization Practices (ACIP). Topics include updated recommendation for influenza vaccines and pneumococcal vaccines and additional information for other vaccines was added; notes in alphabetical order for each vaccine are presented; and the vaccines are distributed in three charts.
- Published
- 2023
- Full Text
- View/download PDF
5. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger -- United States, 2023.
- Author
-
Wodi, A. Patricia, Murthy, Neil, McNally, Veronica, Cineas, Sybil, and Ault, Kevin
- Subjects
- *
IMMUNIZATION of children , *INFLUENZA vaccines , *COVID-19 vaccines , *MEDICAL protocols - Abstract
The article focuses on the Recommendation of Immunization Schedule for Child and Adolescent of ages eighteen and below by the Advisory Committee on Immunization Practices (ACIP). Topics include the updated recommendations added influenza vaccine, pneumococcal conjugate vaccine, measles, mumps, and rubella vaccine (MMR) and COVID-19 vaccine; the recommendation are made after reviews of vaccine-related data; and medical protocol for vaccination of every vaccines are also presented.
- Published
- 2023
- Full Text
- View/download PDF
6. Booster COVID-19 Vaccinations Among Persons Aged ≥5 Years and Second Booster COVID-19 Vaccinations Among Persons Aged ≥50 Years -- United States, August 13, 2021-August 5, 2022.
- Author
-
Fast, Hannah E., Murthy, Bhavini Patel, Zell, Elizabeth, Lu Meng, Murthy, Neil, Saelee, Ryan, Peng-jun Lu, Yoonjae Kang, Shaw, Lauren, Gibbs-Scharf, Lynn, and Harris, LaTreace
- Subjects
COVID-19 vaccines ,BOOSTER vaccines ,OLDER people ,COVID-19 - Published
- 2022
- Full Text
- View/download PDF
7. Factors Associated with Delayed or Missed Second-Dose mRNA COVID-19 Vaccination among Persons >12 Years of Age, United States.
- Author
-
Lu Meng, Murthy, Neil Chandra, Murthy, Bhavini Patel, Zell, Elizabeth, Ryan Saelee, Irving, Megan, Fast, Hannah E., Roman, Patricia Castro, Schiller, Adam, Shaw, Lauren, Black, Carla L., Gibbs-Scharf, Lynn, Harris, LaTreace, and Chorba, Terence
- Abstract
To identify demographic factors associated with delaying or not receiving a second dose of the 2-dose primary mRNA COVID-19 vaccine series, we matched 323 million single Pfizer-BioNTech (https://www.pfizer.com) and Moderna (https://www.modernatx.com) COVID-19 vaccine administration records from 2021 and determined whether second doses were delayed or missed. We used 2 sets of logistic regression models to examine associated factors. Overall, 87.3% of recipients received a timely second dose (≤42 days between first and second dose), 3.4% received a delayed second dose (>42 days between first and second dose), and 9.4% missed the second dose. Persons more likely to have delayed or missed the second dose belonged to several racial/ethnic minority groups, were 18-39 years of age, lived in more socially vulnerable areas, and lived in regions other than the northeastern United States. Logistic regression models identified specific subgroups for providing outreach and encouragement to receive subsequent doses on time. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Disparities in First Dose COVID-19 Vaccination Coverage among Children 5-11 Years of Age, United States.
- Author
-
Murthy, Neil Chandra, Zell, Elizabeth, Fast, Hannah E., Murthy, Bhavini Patel, Lu Meng, Saelee, Ryan, Vogt, Tara, Chatham-Stephens, Kevin, Ottis, Christina, Shaw, Lauren, Gibbs-Scharf, Lynn, Harris, LaTreace, and Chorba, Terence
- Abstract
We analyzed first-dose Coronavirus disease vaccination coverage among US children 5-11 years of age during November-December 2021. Pediatric vaccination coverage varied widely by jurisdiction, age group, and race/ethnicity, and lagged behind vaccination coverage for adolescents aged 12-15 years during the first 2 months of vaccine rollout. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties - United States, December 14, 2020-January 31, 2022.
- Author
-
Saelee, Ryan, Zell, Elizabeth, Murthy, Bhavini Patel, Castro-Roman, Patricia, Fast, Hannah, Lu Meng, Shaw, Lauren, Gibbs-Scharf, Lynn, Chorba, Terence, Harris, LaTreace Q., Murthy, Neil, and Meng, Lu
- Abstract
Higher COVID-19 incidence and mortality rates in rural than in urban areas are well documented (1). These disparities persisted during the B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant surges during late 2021 and early 2022 (1,2). Rural populations tend to be older (aged ≥65 years) and uninsured and are more likely to have underlying medical conditions and live farther from facilities that provide tertiary medical care, placing them at higher risk for adverse COVID-19 outcomes (2). To better understand COVID-19 vaccination disparities between urban and rural populations, CDC analyzed county-level vaccine administration data among persons aged ≥5 years who received their first dose of either the BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccine or a single dose of the Ad.26.COV2.S (Janssen [Johnson & Johnson]) COVID-19 vaccine during December 14, 2020-January 31, 2022, in 50 states and the District of Columbia (DC). COVID-19 vaccination coverage with ≥1 doses in rural areas (58.5%) was lower than that in urban counties (75.4%) overall, with similar patterns across age groups and sex. Coverage with ≥1 doses varied among states: 46 states had higher coverage in urban than in rural counties, one had higher coverage in rural than in urban counties. Three states and DC had no rural counties; thus, urban-rural differences could not be assessed. COVID-19 vaccine primary series completion was higher in urban than in rural counties. However, receipt of booster or additional doses among primary series recipients was similarly low between urban and rural counties. Compared with estimates from a previous study of vaccine coverage among adults aged ≥18 years during December 14, 2020-April 10, 2021, these urban-rural disparities among those now eligible for vaccination (aged ≥5 years) have increased more than twofold through January 2022, despite increased availability and access to COVID-19 vaccines. Addressing barriers to vaccination in rural areas is critical to achieving vaccine equity, reducing disparities, and decreasing COVID-19-related illness and death in the United States (2). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2022.
- Author
-
Murthy, Neil, Wodi, A. Patricia, Bernstein, Henry, McNally, Veronica, Cineas, Sybil, and Ault, Kevin
- Subjects
- *
MEDICAL personnel , *ADULTS , *IMMUNIZATION , *SCHEDULING - Abstract
At its November 2021 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2022. The 2022 adult immunization schedule summarizes ACIP recommendations, including several changes to the cover page, tables, and notes from the 2021 immunization schedule.† In addition, the 2022 adult immunization schedule provides an appendix that lists the contraindications to and precautions for all routinely recommended vaccines in the schedule. This schedule can be found on the CDC immunization schedule website (https://www.cdc.gov/vaccines/schedules). Health care providers are advised to use the cover page, tables, notes, and appendix together. This adult immunization schedule is recommended by ACIP (https://www.cdc.gov/vaccines/acip) and approved by CDC (https://www.cdc.gov), the American College of Physicians (https://www.acponline.org), the American Academy of Family Physicians (https://www.aafp.org), the American College of Obstetricians and Gynecologists (https://www.acog.org), the American College of Nurse-Midwives (https://www.midwife.org), the American Academy of Physician Associates (https://www.aapa.org), and the Society for Healthcare Epidemiology of America (https://www.shea-online.org). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2022.
- Author
-
Wodi, A. Patricia, Murthy, Neil, Bernstein, Henry, McNally, Veronica, Cineas, Sybil, and Ault, Kevin
- Subjects
- *
IMMUNIZATION of children , *MEDICAL personnel , *IMMUNIZATION , *TEENAGERS , *NURSE practitioners - Abstract
At its November 2021 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger-United States, 2022. The 2022 child and adolescent immunization schedule, found on the CDC immunization schedule website (https://www.cdc.gov/vaccines/schedules), summarizes ACIP recommendations, including several changes from the 2021 immunization schedule† on the cover page, tables, and notes. The 2022 child and adolescent schedule also includes a newly created appendix that lists the contraindications and precautions for all vaccine types in the schedule. Health care providers are advised to use the tables, notes, and appendix together. This immunization schedule is recommended by ACIP (https://www.cdc.gov/vaccines/acip) and approved by CDC (https://www.cdc.gov), the American Academy of Pediatrics (https://www.aap.org), the American Academy of Family Physicians (https://www.aafp.org), the American College of Obstetricians and Gynecologists (http://www.acog.org), the American College of Nurse-Midwives (https://www.midwife.org), the American Academy of Physician Associates (https://www.aapa.org), and the National Association of Pediatric Nurse Practitioners (https://www.napnap.org). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years - United States, August 13, 2021-November 19, 2021.
- Author
-
Fast, Hannah E., Zell, Elizabeth, Patel Murthy, Bhavini, Murthy, Neil, Lu Meng, Gibbs Scharf, Lynn, Black, Carla L., Shaw, Lauren, Chorba, Terence, Harris, LaTreace Q., Murthy, Bhavini Patel, Meng, Lu, and Scharf, Lynn Gibbs
- Abstract
Vaccination against SARS-CoV-2 (the virus that causes COVID-19) is highly effective at preventing hospitalization due to SARS-CoV-2 infection and booster and additional primary dose COVID-19 vaccinations increase protection (1-3). During August-November 2021, a series of Emergency Use Authorizations and recommendations, including those for an additional primary dose for immunocompromised persons and a booster dose for persons aged ≥18 years, were approved because of reduced immunogenicity in immunocompromised persons, waning vaccine effectiveness over time, and the introduction of the highly transmissible B.1.617.2 (Delta) variant (4,5). Adults aged ≥65 years are at increased risk for COVID-19-associated hospitalization and death and were one of the populations first recommended a booster dose in the U.S. (5,6). Data on COVID-19 vaccinations reported to CDC from 50 states, the District of Columbia (DC), and eight territories and freely associated states were analyzed to ascertain coverage with booster or additional primary doses among adults aged ≥65 years. During August 13-November 19, 2021, 18.7 million persons aged ≥65 years received a booster or additional primary dose of COVID-19 vaccine, constituting 44.1% of 42.5 million eligible* persons in this age group who previously completed a primary vaccination series.† Coverage was similar by sex and age group, but varied by primary series vaccine product and race and ethnicity, ranging from 30.3% among non-Hispanic American Indian or Alaska Native persons to 50.5% among non-Hispanic multiple/other race persons. Strategic efforts are needed to encourage eligible persons aged ≥18 years, especially those aged ≥65 years and those who are immunocompromised, to receive a booster and/or additional primary dose to ensure maximal protection against COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. COVID-19 Vaccination Coverage Among Adolescents Aged 12-17 Years - United States, December 14, 2020-July 31, 2021.
- Author
-
Murthy, Bhavini Patel, Zell, Elizabeth, Saelee, Ryan, Murthy, Neil, Lu Meng, Meador, Seth, Reed, Kirsten, Shaw, Lauren, Gibbs-Scharf, Lynn, McNaghten, A. D., Patel, Anita, Stokley, Shannon, Flores, Stephen, Yoder, Jonathan S., Black, Carla L., Harris, LaTreace Q., and Meng, Lu
- Subjects
COVID-19 vaccines ,MEDICAL personnel ,TEENAGERS ,SOCIAL emotional learning ,VACCINE hesitancy - Abstract
Although severe COVID-19 illness and hospitalization are more common among adults, these outcomes can occur in adolescents (1). Nearly one third of adolescents aged 12-17 years hospitalized with COVID-19 during March 2020-April 2021 required intensive care, and 5% of those hospitalized required endotracheal intubation and mechanical ventilation (2). On December 11, 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine for adolescents aged 16-17 years; on May 10, 2021, the EUA was expanded to include adolescents aged 12-15 years; and on August 23, 2021, FDA granted approval of the vaccine for persons aged ≥16 years. To assess progress in adolescent COVID-19 vaccination in the United States, CDC assessed coverage with ≥1 dose* and completion of the 2-dose vaccination series† among adolescents aged 12-17 years using vaccine administration data for 49 U.S. states (all except Idaho) and the District of Columbia (DC) during December 14, 2020-July 31, 2021. As of July 31, 2021, COVID-19 vaccination coverage among U.S. adolescents aged 12-17 years was 42.4% for ≥1 dose and 31.9% for series completion. Vaccination coverage with ≥1 dose varied by state (range = 20.2% [Mississippi] to 70.1% [Vermont]) and for series completion (range = 10.7% [Mississippi] to 60.3% [Vermont]). By age group, 36.0%, 40.9%, and 50.6% of adolescents aged 12-13, 14-15, and 16-17 years, respectively, received ≥1 dose; 25.4%, 30.5%, and 40.3%, respectively, completed the vaccine series. Improving vaccination coverage and implementing COVID-19 prevention strategies are crucial to reduce COVID-19-associated morbidity and mortality among adolescents and to facilitate safer reopening of schools for in-person learning. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties - United States, December 14, 2020-April 10, 2021.
- Author
-
Murthy, Bhavini Patel, Sterrett, Natalie, Weller, Daniel, Zell, Elizabeth, Reynolds, Laura, Toblin, Robin L., Murthy, Neil, Kriss, Jennifer, Rose, Charles, Cadwell, Betsy, Wang, Alice, Ritchey, Matthew D., Gibbs-Scharf, Lynn, Qualters, Judith R., Shaw, Lauren, Brookmeyer, Kathryn A., Clayton, Heather, Eke, Paul, Adams, Laura, and Zajac, Julie
- Subjects
COVID-19 vaccines ,HEALTH services administration ,MEDICAL personnel ,HEALTH facilities ,COUNTIES ,RURAL nursing - Abstract
Approximately 60 million persons in the United States live in rural counties, representing almost one fifth (19.3%) of the population.* In September 2020, COVID-19 incidence (cases per 100,000 population) in rural counties surpassed that in urban counties (1). Rural communities often have a higher proportion of residents who lack health insurance, live with comorbidities or disabilities, are aged ≥65 years, and have limited access to health care facilities with intensive care capabilities, which places these residents at increased risk for COVID-19-associated morbidity and mortality (2,3). To better understand COVID-19 vaccination disparities across the urban-rural continuum, CDC analyzed county-level vaccine administration data among adults aged ≥18 years who received their first dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine, or a single dose of the Janssen COVID-19 vaccine (Johnson & Johnson) during December 14, 2020-April 10, 2021 in 50 U.S. jurisdictions (49 states and the District of Columbia [DC]). Adult COVID-19 vaccination coverage was lower in rural counties (38.9%) than in urban counties (45.7%) overall and among adults aged 18-64 years (29.1% rural, 37.7% urban), those aged ≥65 years (67.6% rural, 76.1% urban), women (41.7% rural, 48.4% urban), and men (35.3% rural, 41.9% urban). Vaccination coverage varied among jurisdictions: 36 jurisdictions had higher coverage in urban counties, five had higher coverage in rural counties, and five had similar coverage (i.e., within 1%) in urban and rural counties; in four jurisdictions with no rural counties, the urban-rural comparison could not be assessed. A larger proportion of persons in the most rural counties (14.6%) traveled for vaccination to nonadjacent counties (i.e., farther from their county of residence) compared with persons in the most urban counties (10.3%). As availability of COVID-19 vaccines expands, public health practitioners should continue collaborating with health care providers, pharmacies, employers, faith leaders, and other community partners to identify and address barriers to COVID-19 vaccination in rural areas (2). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Vaccination Coverage Among Children Aged 2 Years - U.S. Affiliated Pacific Islands, April-October, 2016.
- Author
-
Tippins, Ashley, Murthy, Neil, Meghani, Mehreen, Solsman, Amy, Apaisam, Carter, Basilius, Merlyn, Eckert, Maribeth, Judicpa, Peter, Masunu, Yolanda, Pistotnik, Kelsey, Pedro, Daisy, Sasamoto, Jeremy, and Underwood, J. Michael
- Subjects
- *
VACCINATION of children , *IMMUNIZATION of children , *DPT vaccines , *HEPATITIS B vaccines , *PUBLIC health , *PEDIATRICS - Abstract
Vaccine-preventable diseases (VPDs) cause substantial morbidity and mortality in the United States Affiliated Pacific Islands (USAPI).* CDC collaborates with USAPI immunization programs to monitor vaccination coverage. In 2016, † USAPI immunization programs and CDC piloted a method for estimating up-to-date status among children aged 2 years using medical record abstraction to ascertain regional vaccination coverage. This was the first concurrent assessment of childhood vaccination coverage across five USAPI jurisdictions (American Samoa; Chuuk State, Federated States of Micronesia [FSM]; Commonwealth of the Northern Mariana Islands [CNMI]; Republic of the Marshall Islands [RMI]; and Republic of Palau).§ Differences in vaccination coverage between main and outer islands¶ were assessed for two jurisdictions where data were adequate.** Series coverage in this report includes the following doses of vaccines: ≥4 doses of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP); ≥3 doses of inactivated poliovirus vaccine (IPV); ≥1 dose of measles, mumps, and rubella vaccine (MMR); ≥3 doses of Haemophilus influenzae type B (Hib) vaccine; ≥3 doses of hepatitis B (HepB) vaccine; and ≥4 doses of pneumococcal conjugate vaccine (PCV); i.e., 4:3:1:3:3:4. Coverage with ≥3 doses of rotavirus vaccine was also assessed. Completion of the recommended series of each of these vaccines†† was <90% in all jurisdictions except Palau. Coverage with the full recommended six-vaccine series (4:3:1:3:3:4) ranged from 19.5% (Chuuk) to 69.1% (Palau). In RMI and Chuuk, coverage was lower in the outer islands than in the main islands for most vaccines, with differences ranging from 0.9 to 66.8 percentage points. Medical record abstraction enabled rapid vaccination coverage assessment and timely dissemination of results to guide programmatic decision-making. Effectively monitoring vaccination coverage, coupled with implementation of data-driven interventions, is essential to maintain protection from VPD outbreaks in the region and the mainland United States. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
16. Progress in Childhood Vaccination Data in Immunization Information Systems - United States, 2013-2016.
- Author
-
Murthy, Neil, Rodgers, Loren, Pabst, Laura, Fiebelkorn, Amy Parker, and Ng, Terence
- Abstract
In 2016, 55 jurisdictions in 49 states and six cities in the United States* used immunization information systems (IISs) to collect and manage immunization data and support vaccination providers and immunization programs. To monitor progress toward achieving IIS program goals, CDC surveys jurisdictions through an annual self-administered IIS Annual Report (IISAR). Data from the 2013-2016 IISARs were analyzed to assess progress made in four priority areas: 1) data completeness, 2) bidirectional exchange of data with electronic health record systems, 3) clinical decision support for immunizations, and 4) ability to generate childhood vaccination coverage estimates. IIS participation among children aged 4 months through 5 years increased from 90% in 2013 to 94% in 2016, and 33 jurisdictions reported ≥95% of children aged 4 months through 5 years participating in their IIS in 2016. Bidirectional messaging capacity in IISs increased from 25 jurisdictions in 2013 to 37 in 2016. In 2016, nearly all jurisdictions (52 of 55) could provide automated provider-level coverage reports, and 32 jurisdictions reported that their IISs could send vaccine forecasts to providers via Health Level 7 (HL7) messaging, up from 17 in 2013. Incremental progress was made in each area since 2013, but continued effort is needed to implement these critical functionalities among all IISs. Success in these priority areas, as defined by the IIS Functional Standards (1), bolsters clinicians' and public health practitioners' ability to attain high vaccination coverage in pediatric populations, and prepares IISs to develop more advanced functionalities to support state/local immunization services. Success in these priority areas also supports the achievement of federal immunization objectives, including the use of IISs as supplemental sampling frames for vaccination coverage surveys like the National Immunization Survey (NIS)-Child, reducing data collection costs, and supporting increased precision of state-level estimates. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
17. Notes from the Field: Absence of Asymptomatic Mumps Virus Shedding Among Vaccinated College Students During a Mumps Outbreak - Washington, February-June 2017.
- Author
-
Bonwitt, Jesse, Kawakami, Vance, Wharton, Adam, Burke, Rachel M, Murthy, Neil, Lee, Adria, Dell, BreeAnna, Kay, Meagan, Duchin, Jeff, Hickman, Carole, McNall, Rebecca J, Rota, Paul A, Patel, Manisha, Lindquist, Scott, DeBolt, Chas, and Routh, Janell
- Published
- 2017
- Full Text
- View/download PDF
18. Absence of Asymptomatic Mumps Virus Shedding Among Vaccinated College Students During a Mumps Outbreak -- Washington, February-June 2017.
- Author
-
Bonwitt, Jesse, Kawakami, Vance, Wharton, Adam, Burke, Rachel M., Murthy, Neil, Lee, Adria, Dell, BreeAnna, Kay, Meagan, Duchin, Jeff, Hickman, Carole, McNall, Rebecca J., Rota, Paul A., Patel, Manisha, Lindquist, Scott, DeBolt, Chas, and Routh, Janell
- Subjects
MUMPS ,MUMPS vaccines ,PAROTITIS ,DISEASE prevalence ,EPIDEMIOLOGY ,SYMPTOMS ,STUDENTS - Abstract
A study which assessed the prevalence, symptoms and associated risk factors of asymptomatic mumps virus shedding in a sample of vaccinated college students of the University of Washington (UW), Seattle campus, is presented. Topics covered include the symptoms experienced by the participants, occurrence of the outbreak among fraternity and sorority members, and the number of confirmed and probable mumps cases.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.